Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TACR2 | P21452 | 2/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | PDE2A | O00408 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | GJB2 | P29033 | 1/20 | 0.38 |
| ▸ | HOGA1 | Q86XE5 | 1/20 | 0.37 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | NT5E | P21589 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16158856 | 1.00 | SLC6A2 (0.46) | SLC6A2HSPA5TSHRTACR2PDE4D | |
| SCHEMBL15869485 | 0.88 | SLC6A2 (0.44) | SLC6A2HSPA5TSHRTACR2PDE4D | |
| SCHEMBL22677691 | 0.88 | SLC6A2 (0.44) | SLC6A2HSPA5TSHRTACR2PDE4D | |
| SCHEMBL12136335 | 0.87 | SLC6A2 (0.46) | SLC6A2HSPA5TSHRTACR2PDE4D | |
| SCHEMBL16158862 | 0.86 | TSHR (0.44) | SLC6A2TSHRPDE4DHTTSSTR4 | |
| SCHEMBL16158879 | 0.86 | TSHR (0.44) | SLC6A2TSHRPDE4DHTTSSTR4 | |
| SCHEMBL16625047 | 0.86 | TSHR (0.44) | SLC6A2TSHRPDE4DHTTSSTR4 | |
| SCHEMBL18499302 | 0.86 | TSHR (0.44) | SLC6A2TSHRPDE4DHTTSSTR4 | |
| SCHEMBL14413233 | 0.86 | TACR2 (0.48) | SLC6A2TACR2PDE4DGJB2SSTR4 | |
| SCHEMBL14039087 | 0.86 | SLC6A2 (0.46) | SLC6A2HSPA5TSHRTACR2PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110144042-A1 | Novel Polysaccharides with Antithrombotic Activity Comprising at Least One Covalent Bond with Biotin or a Biotin Derivative | SANOFI-AVENTIS (FR) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144042-A1 | Novel Polysaccharides with Antithrombotic Activity Comprising at Least One Covalent Bond with Biotin or a Biotin Derivative | SERPINC1, SELP, FGB | SLC6A2 4762/4885HSPA5 3361/4885TSHR 2341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.